Patents by Inventor Kristoffer Hellstrand

Kristoffer Hellstrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210187072
    Abstract: Some embodiments provided herein relate to methods and compositions for reducing the risk of relapse of a hyperproliferative disorder, such as acute myeloid leukemia (AML), in a subject in which the hyperproliferative cells of the subject exhibit a normal karyotype and/or in a subject who has been administered no more than one induction therapeutic course. Some such embodiments include the administration of a NOX2 inhibitor, such as histamine dihydrochloride (HDC), in combination with a cytokine, such as interleukin-2 (L-2).
    Type: Application
    Filed: June 20, 2019
    Publication date: June 24, 2021
    Inventors: Anna MARTNER, Fredrik Bergh THOREN, Kristoffer HELLSTRAND
  • Publication number: 20200399642
    Abstract: Some embodiments of the methods and compositions provided herein relate to the treatment and amelioration of metastatic tumors and to the prevention of distant metastasis. In some embodiments, a metastatic tumor, such as a melanoma, can be treated by reducing the activity of NOX2 in a cell of a subject. In some embodiments, the activity of NOX2 can be reduced by administering a NOX2 inhibitor, such as histamine dihydrochloride (HDC).
    Type: Application
    Filed: January 27, 2020
    Publication date: December 24, 2020
    Inventors: Anna Martner, Kristoffer Hellstrand
  • Publication number: 20200222505
    Abstract: Disclosed herein include methods of delaying and preventing acute myeloid leukemia (AML) relapse in patients with mutant nucleophosmin 1 (NPM1) by co-administration of histamine, or derivatives thereof, and interleukin-2 (IL-2). In some embodiments, an unexpected delay in and/or prevention of relapse results in a surprising increase in leukemia- free survival rate and overall survival rate.
    Type: Application
    Filed: June 28, 2018
    Publication date: July 16, 2020
    Inventors: Anna Martner, Fredrik Bergh Thorén, Johan Aurelius, Kristoffer Hellstrand
  • Publication number: 20120039844
    Abstract: An improved composition and method for reducing the formation of oxygen radicals in mononuclear phagocytes is disclosed. Also provided is a method of protecting NK cells from oxidative damage inflicted by radicals produced by mononuclear phagocytes by administering a histamine metabolite, N-alpha-methylhistamine dihydrochloride. Use of N-alpha-methylhistamine dihydrochloride for enhancing the NK cell response to IL-2 is likewise detailed.
    Type: Application
    Filed: April 9, 2010
    Publication date: February 16, 2012
    Inventor: Kristoffer Hellstrand
  • Publication number: 20060079510
    Abstract: Method and composition for protecting tumorcidal lymphocytes including cytotoxic lymphocytes and NK cells from apoptosis and down regulation are provided. The method and composition include the administration of an effective amount of a PARP-1 inhibitor to a population of cytotoxic T lymphocytes and NK cells in the presence of monocytes or macrophages. In some embodiments, the method and composition additionally include the administration of a reactive oxygen metabolite (ROM) production or release inhibitory compound. Methods of treating cancer, viral diseases, and inflammatory diseases with a PARP-1 inhibitor are likewise provided.
    Type: Application
    Filed: September 29, 2005
    Publication date: April 13, 2006
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Fredrik Thoren, Ana Romero
  • Patent number: 6893633
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 17, 2005
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Patent number: 6821510
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: November 23, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20040219153
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 4, 2004
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20040191239
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: April 7, 2004
    Publication date: September 30, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6790440
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: September 14, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20040120926
    Abstract: Compositions and methods for treating a variety of conditions in which a reactive oxygen metabolite (ROM) inhibitor or scavenger is administered alone or in conjunction with additional agents. Such conditions include, cancer, viral diseases, and inflammatory diseases, for example.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 24, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6730692
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: May 4, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6613788
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 2, 2003
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030149090
    Abstract: Described herein are compositions and methods for the treatment of microbial infection.
    Type: Application
    Filed: November 5, 2002
    Publication date: August 7, 2003
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand
  • Publication number: 20030039628
    Abstract: The present invention relates to a method for facilitating activation of T-cells in a patient, comprising: identifying a patient in need of enhanced T-cell activity, administering an effective amount of a T-cell activating composition to the patient, and administering an effective amount of a compound that inhibits the production or release of intercellular reactive oxygen metabolites (ROM) to the patient. The present invention further relates to the use of H2-receptor agonists to augment the effectiveness of vaccines.
    Type: Application
    Filed: October 3, 2002
    Publication date: February 27, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030017145
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: September 19, 2002
    Publication date: January 23, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6498181
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: December 24, 2002
    Assignee: Maxim Pharmaceuticals
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020193416
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: August 9, 2002
    Publication date: December 19, 2002
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020182174
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182175
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen